Intercept Pharmaceuticals, Inc. (ICPT)
| Market Cap | 560.44M |
| Revenue (ttm) | 321.70M |
| Net Income (ttm) | -222.32M |
| Shares Out | 33.16M |
| EPS (ttm) | -6.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $16.90 |
| Previous Close | $17.19 |
| Change ($) | -0.29 |
| Change (%) | -1.69% |
| Day's Open | 17.15 |
| Day's Range | 16.58 - 17.57 |
| Day's Volume | 711,545 |
| 52-Week Range | 13.88 - 55.59 |
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The biotech can't seem to catch a break.
NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
Reddit's retail investors may soon be swooning over this under-the-radar trio of heavily short-sold companies.
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength do...
Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.
New contraindication applies to a subset of patients with primary biliary cholangitis (PBC) with decompensated cirrhosis, a prior decompensation event, or with compensated cirrhosis who have evidence of...
The FDA has issued a statement restricting the use of Intercept Pharmaceuticals Inc's (NASDAQ: ICPT) Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis. PBC...
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat prog...
Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations.
Intercept (ICPT) delivered earnings and revenue surprises of 20.26% and 1.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Worldwide Ocaliva® net sales of $81.7M, representing 12% growth over the prior year quarter
Analysts believe these underperformers could nearly double over the next 12 months.
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results?
Analysts' consensus price targets imply that these stocks can more than double over the next 12 months.
Hint: They're not AMC Entertainment, GameStop, or Sundial Growers.
Bargains abound for growth seekers and value investors.
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?
You've probably never heard about these fast-paced companies before, but Wall Street believes they can make you a boatload of money.
NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pr...
Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.
Intercept (ICPT) delivered earnings and revenue surprises of -1.94% and -0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Worldwide Ocaliva ® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercept's Executive Leadership Team
NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
These bounce-back plays might be diamonds in the rough.
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat pro...
Intercept has suffered an important set back with the FDA's CRL for Ocaliva in NASH with liver fibrosis. Ocaliva may still be approvable in NASH and the risk-reward for ICPT is more appealing at current...
New York, New York--(Newsfile Corp. - January 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of In...
New York, New York--(Newsfile Corp. - January 4, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...
LOS ANGELES, Jan. 4, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. ("Int...
NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ...
NEW YORK, Jan. 2, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) and certai...
New York, New York--(Newsfile Corp. - January 2, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) betwee...
NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...
LOS ANGELES--(BUSINESS WIRE)---- $ICPT #classaction--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. (ICPT)
New York, New York--(Newsfile Corp. - December 28, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...
NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United Sta...
New York, New York--(Newsfile Corp. - December 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) betwe...
NEW YORK, NY / ACCESSWIRE / December 28, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a...
About ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in vario... [Read more...]
| Industry Biotechnology | IPO Date Oct 11, 2012 |
| Stock Exchange NASDAQ | Ticker Symbol ICPT |
Financial Performance
In 2020, ICPT's revenue was $312.69 million, an increase of 24.08% compared to the previous year's $252.00 million. Losses were -$274.88 million, -20.25% less than in 2019.
Analyst Forecasts
According to 24 analysts, the average rating for ICPT stock is "Buy." The 12-month stock price forecast is 34.81, which is an increase of 105.98% from the latest price.